Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven ...Middle East

TOKYO and CAMBRIDGE, England, June 23, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company"; TSE: 4565) today announces that the first healthy subject has been dosed with HTL0022562 in a Phase 1 clinical study. HTL0022562 (also known as BHV3100) is a novel, small molecule CGRP*...

Hence then, the article about sosei heptares initiates phase 1 trial with novel small molecule cgrp antagonist under collaboration with biohaven was published today ( Wednesday 23/06/2021 - 10:30 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven )

Also on site :

• Who Is Anthony Kazmierczak? Ilhan Omar Attack Suspect Identified
• Country Star Forced to Postpone Sold-Out  Minneapolis Show Due to ‘Safety’ Concerns: ‘I’m Not Here to Act Oblivious’
• Trump-Putin photo spotted at White House